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Almost90% of patients resuscitated from out of hospital
cardiac arrest have coronary heart disease and can be
categorized in one of three groups: acute myocardial
infarction, ischemicevent or primary arrhythmic event.
The patients who have acute myocardial infarction have
the best prognosis, and those with primary arrhythmic
events have the worst. Recent studies show that ven-
tricular arrhythmias after myocardial infarction are as-
sociated with mortality indejH:ndent of any association
with left ventricular dysfunction. Ventricular arrhyth-
mias that have caused cardiac arrest or hemodynamic
collapse, that is, malignantarrhythmias, shouldbe treated
aggressively and evaluated carefully with one of two
methods that have high predictive accuracy for outcome:
The problem of sudden cardiac death is primarily one of
malignant or potentially malignant ventricular arrhythmias
in coronary heart disease. As noted elsewhere in this issue,
the ventricular arrhythmias in coronary heart disease have
a diverse pathophysiology. This report reviews approaches
to secondary prevention of ventricular arrhythmias in pa-
tients with coronary heart disease.
Pathophysiology of Ventricular Arrhythmias
Out of Hospital Cardiac Arrest
Almost 90% of patients resuscitated from out of hospital
cardiac arrest have coronary heart disease. For 20%, the
cardiac arrest is the initial manifestation of heart disease.
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1) the Holter recording/exercise test approach, or 2) the
electrophysiologicapproach.
It is not yet known whether treating potentially ma-
lignant ventricular arrhythmias after myocardial in-
farction with class I or III antiarrhythmic drugs will
reduce mortality, but two clinical trials are under way
in the United States to address this question. Beta-ad-
renergic blOCking drugs do reducemortahty, probably
as a result of both antiischemlc and antiarrhythmif: ef-
fects. Calcium channel blocking agents, various anti-
platelet drugs and alpha-adrenergic blocking drugs are
under investigationto determine their value in secondary
prevention of ventricular fibrillation.
(J Am Coli CardioI1985;5:23B-26B)
The survivors of cardiac arrest who have coronary heart
disease can be categorized in three groups: those with an
acute myocardial infarction, an ischemic event or primary
arrhythmic event (Table I) (1-5). Those with an acute myo-
cardial infarction are the youngest, have the lowest preva-
lence of previous myocardial infarction and left ventricular
dysfunction and have the best long-term survival rate. Pa-
tients with primary arrhythmic events are the oldest group,
have the highest prevalence of previous myocardial infarc-
tion and left ventricular dysfunction and have the worst long-
term survival rate.
Cardiac catheterization in survivors of out of hospital
cardiac arrest shows a high prevalence of two or three vessel
coronary artery disease and left ventricular dysfunction as
judged by global left ventricular ejection fraction and wall
motion abnormalities (6). Holter ambulatory electrocardio-
graphic recordings show a high prevalence of frequent and
repetitive ventricular premature depolarizations in survivors
of cardiac arrest (6). Electrophysiologic studies (7-9) have
demonstrated that programmed ventricular stimulation can
elicit ventricular tachycardia or ventricular fibrillation in
about 70% of survivors of out of hospital cardiac arrest.
The likelihood of obtaining this response is greater in pa-
tients with previous myocardial infarction and pronounced
left ventricular dysfunction.
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Table 1. Characteristics of Patients With Out of Hospital Cardiac Arrest
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Acute
Study No. of Infarction Ischemia
(first author) Year Patients (%) (%)
Liberthson (I) 1974 80 39 34
Baum (2) 1974 146 19 38
Myerberg (4) 1980 117 36
Goldstein (5) 1981 142 44 34
Previous
Infarction
(%)
46
Neither
Ischemia nor
Infarction
(%)
19
43
22
Table 2. Independent Relation Among Ventricular
Arrhythmia, Left Ventricular Dysfunction and Mortality After
Myocardial Infarction
dysfunction that they do not contribute independently to
mortality, and 2) the presence of ventricular arrhythmias is
a risk factor for subsequent mortality independent of any
~ffect of left ventricular dysfunction. If the first hypothesis
IS true, treatment of potentially malignant ventricular ar-
rhythmias with antiarrhythmic drugs would be irrational. If
the second hypothesis is true, treatment would have a strong
rationale.
Predictive role of ventricular arrhythmia versus left
ventricular dysfunction. The major studies of the relations
among ventricular arrhythmias, left ventricular dysfunction
and mortality are summarized in Table 2. Each of the studies
(16-20) used left ventricular ejection fraction and 24 hour
electrocardiographic recordings to evaluate arrhythmias in
postinfarction patients. Schultze et al. (16,17) studied 81
patients, Because all eight deaths in these 81 patients oc-
curred in the subgroup that had a low ejection fraction and
"complex" ventricular arrhythmias, these data cannot be
informative with respect to an interaction between the two
risk factors and mortality. The Multicenter Investigation of
the Limitation of Infarct Size (MILlS) reported findings on
388 patients in 1982 (18) and on 533 patients in 1984 (19),
and the Multicenter Post Infarction Program (MPIP) re-
Data not given.
Malignant Ventricular Arrhythmias
A number of studies (10-12) have shown that ventricular
fibrillation is overwhelmingly the most common cause of
sudden cardiac death in patients with coronary heart disease.
However, the pathogenetic sequences that lead to ventricular
fibrillation have not yet been fully elucidated. New knowl-
edge about these sequences will undoubtedly lead to im-
proved secondary prevention with drugs. Clinical studies
suggest that, in general, two major mechanisms of ventric-
ular fibrillation exist in coronary heart disease: 1) myocardial
ischemia and 2) scar-related ventricular tachycardia.
Ischemia. Several events produce myocardial ischemia
that may lead to ventricular fibrillation: 1) increased oxygen
demand in the presence of tight flow-limiting stenosis, 2)
spasm of a coronary artery, usually at the site of a tight
stenosis (13-15), and 3) thrombotic coronary occlusion.
Lethal arrhythmias can occur at the onset of ischemia or at
the time of reperfusion.
Scar-related ventricular tachycardia or fibrilla-
tion. The second common mechanism of malignant ven-
tricular arrhythmias, scar-related ventricular tachycardia or
ventricular fibrillation, usually occurs in patients with pre-
vious myocardial infarction and significant left ventricular
dysfunction. Ventricular aneurysm is common in this group.
Other causes. Malignant ventricular arrhythmias can
occur in other circumstances, such as presence of the con-
genital long QT syndrome or proarrhythmic drug effects.
The latter may be associated with an acquired long QT
syndrome or with marked conduction slowing in the heart. Schultze
(16,17)
Mukharji
(18)
Bigger
(20)
*I year mortality rate; t2 year mortality rate. LVEF = left ventricular
ejection fraction; - = not determined.
Potentially Malignant Ventricular Arrhythmias
It has been recognized for some time that left ventricular
dysfunction and ventricular arrhythmias are both potent pre-
dictors of cardiac death in patients with recent myocardial
infarction. However, the relations among these three vari-
ables have been controversial. The interaction between left
ventricular dysfunction and ventricular arrhythmias with re-
spect to death holds the key to secondary preventive mea-
sures for patients with potentially malignant ventricular ar-
rhythmias. There are two conflicting hypotheses on the
relations among these three variables: 1) ventricular ar-
rhythmias are so strongly associated with left ventricular
Year
No. of patients
LVEF <40%
"Complex" ventricular premature
depolarization
"Complex" ventricular premature
depolarization and LVEF <40%
Overall mortality
Ventricular arrhythmias independent
of left ventricular dysfunction
1977
81
45
(56%)
29
(36%)
26
(32%)
8*
(10%)
1982
388
134
(35%)
102
(26%)
47
(12%)
25*
(6%)
Yes
1984
766
256
(33%)
218
(28%)
99
(13%)
86t
(11%)
Yes
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ported an analysis of 766 patients in 1984 (20) . As univariate
risk factors, repetitive ventricular premature depolarizations
and a left ventricular ejection fraction of less than 40%
predicted subsequent mortality almost equally well in the
MILlS study, whereas in the MPIP study, a left ventricular
ejection fraction of less than 40% was a stronger risk pre-
dictor. In both the MILlS and MPIP studies, repetitive ven-
tricular premature depolarizations were strongly related to
mortality after adjusting for left ventricular dysfunction with
a left ventricular ejection fraction of less than 40% . Because
the risk of dying in the years after myocardial infarction is
independently increased by left ventricular dysfunction and
ventricular arrhythmias, these two factors can be multiplied
to give the overall risk of death during follow-up study.
Secondary Prevention With Drug Treatment
Malignant Ventricular Arrhythmias
There is a strong consensus that malignant ventricular
arrhythmias should be treated vigorously and nonempiri-
cally. Drugs must be selected and evaluated using rigorous
methodology. Two methods have been shown capable of
predicting a good outcome: I) a noninvasive approach using
Holter electrocardiographic recordings and exercise testing
(21), and 2) an electrophysiologic approach using pro-
grammed ventricular stimulation to evaluate treatment
(22-25) . The protocols for these two methods has been
reviewed elsewhere (26) . Both methods are complex, re-
quire a high level of expertise and are time-consuming and
expensive. There has been no direct comparison of the two
methods so that a preference cannot be stated in most cases.
When ventricular tachycardia occurs frequently but does not
cause severe hemodynamic effects, the Holter recording
exercise test approach is preferable. When the frequency of
sustained ventricular tachycardia is low and its hemody-
namic effects are devastating, the electrophysiologic ap-
proach is superior.
Holter recording/exercise test method. Only one group
(21) has reported the long-term outcome of patients with
malignant ventricular arrhythmias who were managed using
the Holter recording/exercise test approach (Table 3). The
probability of death during 3 years of follow-up was much
greater in the patients whose unsustained ventricular tachy-
cardia could not be completely suppressed.
Electrophysiologic method. Several groups have re-
ported on the ability of programmed ventricular stimulation
to guide drug therapy . As an example, in the study of Swer-
dlow et al. (27) (Table 3), the end point for judging drug
effectiveness was a change from sustained ventricular tachy-
cardia or ventricular fibrillation to less than five repetitive
ventricular responses in response to programmed ventricular
stimulation. The risk of death in drug nonresponders was
eight times greater than for drug responders. This result is
Table 3. Outcome of Two Treatment Programs for Malignant
Ventricular Arrhythmias
Drug
Responders
Method of Mortality
Drug Nonresponders
Arrhythmia Control No. Rate" No. Mortality Rate"
Holter monitorl 98 14% 25 84%
exercise test (21)
Electrophysiologic (27) 103 20% 102 68%
•Approximate 3 year mortality rate.
not significantly different from that obtained with the Holter
recording/exercise test approach.
Because there is no controlled comparison with an un-
treated group, we cannot attribute the improved survivorship
in patients who respond to drug therapy to a drug effect. It
is possible that drug response can predict outcome without
directly influencing it. The question of causality between
treatment and response is not a trivial one. If treatment does
not influence outcome, short-term treatment would be useful
for classifying patients, but long-term treatment would merely
expose patients to the risk of adverse drug effects for no
benefit. Controlled trials of treatment for malignant ven-
tricular arrhythmias are difficult but not impossible to de-
sign. With such trials, additional information will be forth-
coming to define the effect of treatment on subsequent
mortality.
Class I Antiarrhythmic Drugs for Potentially
Malignant Ventricular Arrhythmias
With recent studies (18-20) clearly showing that poten-
tially malignant ventricular arrhythmias are independent
predictors of mortality, there is a strong rationale for treating
ventricular arrhythmias in the first year after myocardial
infarction. The next question is: Will reducing potentially
malignant ventricular arrhythmias significantly reduce mor-
tality? Clearly , we do not know the answer to this question.
Two major studies are underway to address this question:
the Cardiac Arrhythmia Pilot Study (CAPS) and the Ti-
molol, Encainide, Sotolol Trial (TEST).
Cardiac Arrhythmia Pilot Study (CAPS). This study
was initiated during the summer of 1983 in 10 centers in
the United States and Canada to determine whether a treat-
ment strategy could be identified that would provide effec-
tive control of potentially malignant ventricular arrhythmias
with an acceptable level of adverse effects. Patients are
enrolled 6 to 60 days after myocardial infarction if they have
the qualifying arrhythmias, either an average of 10 or more
ventricular premature depolarizations per hour for 24 hours
or 5 or more episodes of nonsustained ventricular tachy-
cardia per day. Eligible patients are randomly assigned to
one of five treatment tracks; four tracks provide active an-
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tiarrhythmic drug treatment sequences and one track pro-
vides placebo treatment. Dose adjustment and drug changes
are permitted within the active treatment tracks. The drugs
used in CAPS are encainide, ethmozin, flecainide and imi-
pramine. In CAPS, efficacy is defined as a 70% reduction
in ventricular premature depolarization frequency and a 90%
reduction in runs of ventricular premature depolarizations.
If an effective, safe treatment strategy is identified in CAPS,
a fullscale trial will be considered as a second stage.
Timolol, Encainide, Sotolol Trial (TEST). The 10TEST
hospitals started enrolling postinfarctiort patients in the win-
ter of 1984 to determine whether treatment of patients with
both potentially malignant ventricular arrhythmias and left
ventricular dysfunction (ejection fraction <40%) can reduce
total cardiac mortality and sudden cardiac death. Patients
are enrolled 6 to 28 days after myocardial infarction. To be
eligible for TEST, patients must have an average of 10 or
more ventricular premature depolarizations per hour or un-
sustained ventricular tachycardia as well as a left ventricular
ejection fraction of less than 40%. Patients are randomly
assigned to treatment with one of three drugs: timolol, 10
mg twice a day; encainide, 50 mg twice a day or sotolol,
320 mg twice a day. Treatment will be evaluated by 24
hour electrocardiographic recordings and overall benefit
judged by effect on mortality. TEST will last 3 years and
plans to enroll 900 patients.
References
I. Liberthson RR, Nagel EL, Hirschman JC, Nussenfeld SR, Black-
bourne BD, Davis JH. Pathophysiologic observations in prehospital
ventricular fibrillation and sudden cardiac death. Circulation
1974;49:790-8.
2. Baum RS, Alvarez H III, Cobb LA. Survival after resuscitation from
out-of-hospital ventricular fibrillation. Circulation 1974;50:1231-5.
3. Lovegrove T, Thompson P. The role of acute myocardial infarction
in sudden cardiac death-a statistician's nightmare. Am Heart J
1978;96:711-3.
4. MyerburgRJ, Conde CA, Sung RJ; et al. Clinical, electrophysiologic
and hemodynamic profile of patients resuscitated from prehospital
cardiac arrest. Am J Med 1980;68:568-76.
5. Goldstein S, Landis JR, Leighton R, et al. Characteristics of the
resuscitated out-of-hospital cardiac arrest victim with coronary heart
disease. Circulation 1981;64:977-84.
6. Cobb LA, Werner JA, Trobaugh GB. Sudden cardiac death. I. A
decade's experience with out-of-hospital resuscitation. Mod Concepts
Cardiovasc Dis 1980;49:31-6.
7. Ruskin IN, DiMarco JP, Garan H. Out-of-hospital cardiac arrest.
Electrophysiologic observations and selection of long-term antiar-
rhythmic therapy. N Engl J Med 1980;303:607-13.
8. Josephson ME, Horowitz LN, Spielman SR, Greenspan AM. Elec-
trophysiologic and hemodynamic studies in patients resuscitated from
cardiac arrest. Am J Cardiol 1980;46:948-55.
9. Morady F, Scheinman MM, Hess DS, Sung RJ, Shen E, Shapiro W.
Electrophysiologic testing in the management of survivors of out-of-
hospital cardiac arrest. Am J CardioI1983;51:85-9.
10. Lewis BH, Antman EA, Graboys TB. Detailed analysis of 24-hour
ambulatory electrocardiographic recordings during ventricular fibril-
lation or torsade de pointes. J Am Coli Cardiol 1983;2:426-36.
II. Pratt CM, Francis MI, Luck JC, et al. Analysis of ambulatory elec-
trocardiograms in 15 patients during spontaneous ventricular fibril-
lation with special reference to preceding arrhythmic events. J Am
Coli Cardiol 1983;2:789-97.
12. Pandis I, Morganroth J. Sudden death in hospitalized patients: cardiac
rhythm disturbances by ambulatory electrocardiographic monitoring.
J Am Coil Cardiol 1983;2:798-805.
13. Wiener L, Kasparian H, Duca PR, et al, Spectrum of coronary arterial
spasm. Clinical, angiographic and myocardial metabolic experience
in 29 cases. Am J Cardiol 1976;38:945-55.
14. Maseri A, Severi S, DeNes N, et al. "Variant" angina. One aspect
of a continuous spectrum of vasospastic myocardial ischemic patho-
genetic mechanisms: estimated incidence and clinical and coronary
arteriographic findings in 138 patients. Am J CardioI1978;42:1019-35.
15. Maseri A, L'Abbate A, Chierchia S, et al. Significance of spasm in
the pathogenesis of ischemic heart disease. Am J Cardiol
1979;44:788-97.
16. Schultze RA Jr, Rouleau J, Rigo P, Bowers S, Strauss HW, Pitt B.
Ventricular arrhythmias in the late hospital phase of acute myocardial
infarction: relation of left ventricular function detected by gated cardiac
blood pool scanning. Circulation 1975;52:1006-11.
17. Schultze RA Jr, Strauss HW, Pitt B. Sudden death in the year following
myocardial infarction. Relation to ventricular premature contractions
in the late hospital phase and left ventricular ejection fraction. Am J
Med 1977;62:192-9.
18. Mukharji J, Rude RE, Poole WK, et al. Late sudden death following
acute myocardial infarction, importance of combined presence of re-
petitive ventricular ectopy and left ventricular dysfunction (abstr). Clin
Res 1982;30:108A.
19. Mukharji I, Rude RE, Poole WK, et al. Risk factors for sudden death
following acute myocardial infarction (two year follow-up). Am J
Cardiol 1984;53:31-6.
20. Bigger IT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM and The
Multicenter Post-Infarction Group. The relationship between ventric-
ular arrhythmias, left ventricular dysfunction and mortality in the 2
years after myocardial infarction. Circulation 1984;69:250-8.
21. Graboys TB, Lown B, Podrid PJ, DeSilva R. Long-term survival of
patients with ventricular arrhythmia treated with antiarrhythmic drugs.
Am J Cardiol 1982;50:437-43.
22. Josephson ME, Horowitz LN. Electrophysiologic approach to therapy
of recurrent sustained ventricular tachycardia. Am I Cardiol
1979;43:631-42.
23. Mason JW, Winkle RA. Accuracy of the ventricular tachycardia-
induction study for predicting long-term efficacy and inefficacy of
antiarrhythmic drugs. N Engl J Med 1980;303:1073-7.
24. Horowitz LN, Josephson ME, Kastor JA. Intracardiac electrophysi-
ologic studies as a method for the optimization of drug therapy in
chronic ventricular arrhythmia. Prog Cardiovasc Dis 1980;23:81-98.
25. Ruskin IN, DiMarco JP, Garan H. Out-of-hospital cardiac arrest.
Electrophysiologic observations and selection of long-term antiar-
rhythmic therapy. N Engl J Med 1980;303:607-13.
26. Bigger IT Jr. Antiarrhythmic treatment: an overview. Am J Cardiol
1984;53:8b-16b.
27. Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in
patients wtih ventricular tachyarrhythmias. N Engl J Med
1983;308:1436-42.
